Reduced IL-2 level concentration in patients with breast cancer as a possible risk factor for relapse

European Journal of Gynaecological Oncology

Volumn 17, Issue 6, 1996, Pages 535-537

  Arduino, S ^a   Tessarolo, M ^a   Bellino, R ^a   Colombatto, S ^a   Leo, L ^a   Wierdis, T ^a   Lanza, A ^a,b  

^a UNIVERSITY OF TURIN   (Italy)

^b NONE   (Italy)

Author keywords

Breast cancer; Interleukin; Relapse

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; EPIRUBICIN; FLUOROURACIL; INTERLEUKIN 2; METHOTREXATE;

ADULT; AGED; ARTICLE; BREAST CANCER; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC VALUE; FEMALE; HUMAN; IMMUNE RESPONSE; MASTECTOMY; PROGNOSIS; RELAPSE; RISK FACTOR; SEGMENTAL MASTECTOMY;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; FEMALE; HUMANS; INTERLEUKIN-2; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; RISK FACTORS; SENSITIVITY AND SPECIFICITY;

EID: 0029847874     PISSN: 03922936     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Lissoni P., Barni S., Rovelli F., Tancini G.: "Lower survival in metastatic cancer patients with reduced Interleukin 2 blood concentrations". Oncology, 1991, 48, 125.
2. Nakayama E., Asano S., Takuwa N., Yokota J., Miwa S.: "Decreased TCGF activity in the culture medium of PHA stimulated peripheral mononuclear cells from patients with metastatic cancer". Clin. exp. Immunol., 1983, 57, 511.
3. Mantovani G., Coiana A., Cossu F., Floris C., Proto E., Macciò A. et al.: "Peripheral blood lymphocyte response to exogenous interleukin 2 by PHA-prestimulated and non PHA-prestimulated cells in patients with cancer". Tumori. 1986, 72, 375.
4. Wanebo H. J., Pace R., Hargett S., Katz D., Sando J.: "Production of and response to interleukin-2 in peripheral blood lymphocytes of cancer patients". Cancer, 1986, 57, 656.
5. Romagnani S.: "Human Th 1 and Th 2 subsets: doubt no more". Immunol Today. 1994, 15, 301.
6. Daynes R. A., Araneo A., Dowell T. A., Huang K., Dudley D.: "Regulation of murine lymphokine production in vivo". J. Exp Med., 1990, 171, 979.
7. Rook G. A. W., Hernandez-Pando R., Ligtman S., "Hormones, peripherally active prohormones and regulation of Th1/Th2 balance". Immunol Today. 1994, 15, 301.
8. Reed M. J., Purohit A., Duncan L. J., Singh A., Roberts C. J., Williams G. J. et al.: "The role of Cytokines and sulphatase inhibitors in regulating oestrogen synthesis in breast tumours". J. Steroid. Biochem. Molec. Biol., 1995, 53, 413.
9. Anastasopulos E., Reclos G. J., Baxevanis C. N., Tsilvakos V., Panagiotopulos N., Fotious S. et al.: "Monocyte disorders associated with T cell defects in cancer patients with solid tumors". Anticancer Res., 1992, 12, 489.
10. Baxevanis C. N., Recios G. J., Gritzapis A. D., Dedousis G. V. Z., Missitzis I., Papamichail M.: "Elevated prostaglandin E2 production by monocytes is responsible for the depressed levels of natural killer and lymphokine activated killer cell function in patients with breast cancer". Cancer. 1993, 72, 491.
11. Fisher B , Slack N. H., Bross I. D. J.: "Cancer of the breast: size of the neoplasm and prognosis". Cancer, 1969, 24, 1071.
12. Kaufmann M., Klinga K., Kuhn W., Abel U.: "Proliferations-index, axillarer lymphknotenstatus. hormonrezeptoren und alter als prognosefaktoren beim primaren mammakarzinom". Geburish. Frauenheilk., 1989, 49, 104.
13. Harris J. R., Henderson I. G.: "Natural history and staging of breast cancer". In: Harris J. R. Hellman S., Henderson I. G. Kinne D.: "Breast disease". Philadelphia. Lippincont. 1987, 267.
14. Blaney R. W., Bishop H. M., Blade J. R. S., Doyle P. J., Elston C. W., Haylittle J. W. et al.: "Relationship between primary breast tumor receptor status and patient survival". Cancer, 1980, 46, 2765.
15. Hilf R., Feldstein M. C., Gibson S. L., Savlow E. D.: "The relative importance of estrogen receptor analysis as a prognostic factor for recurrence or response to chemotherapy in women with breast cancer". Cancer, 1980, 45, 1993.
16. Black M. M., Leis H. P., Shore B., Zachrau R. E.: "Cellular hypersensitivity to breast cancer assessment by a leukocyte migration procedure". Cancer, 1974, 33, 952.
17. Adler A., Stein J. A., Ben-Efraim S.: "Immunocompetence, immunosupression and human breast cancer. II. Further evidence of initial immune impairment by integrated assessment effect of nodal involvement (N) and of primary tumor size (T)". Cancer. 1980, 45, 2061.
18. Baral E., Blomgren H., Petrini B., Wasserman J., Ogenstad S., Silfversward C.: "Prognostic revelance of immunologic variables in breast carcinoma". Act. Rad. Ther. Phys. Bio.: 1977, 16, 417.
19. Eilber F. R., Morton D. L.: "Impaired immunological reactivity and recurrence following cancer surgery". Cancer. 1970, 23, 362.
20. Eilber F. R., Nizza J. A., Morton D. L., "Sequential evaluation of general immune competence in cancer patients and their correlation with clinical course". Cancer, 1975, 35, 660.
21. Hacene K., Despaces A.: "Competetive prognostic value of clinico-pathologic and bioimmunoiogic factors in primary breast cancer". Cancer, 1986, 57, 245.
22. Krown S. E., Prinsky C. M., Wanebo H. J., Brown D. M., Wong P. P., Dettgen D. F.: "Immunologic creativity and prognosis in breast cancer". Cancer, 1980, 46, 1746.
23. Lee Y. T. N,. Lee M.: "Delayed cutaneous hypersensivity. lymphocyte count, blood tests in patients with breast cancer". J. Surg. Oncol., 1984, 27, 135.
24. Nemoto T., Han T., Monowada J., Angkur V.: "Cell-mediated immune status of breast cancer patients: evaluation by skin test, lymphocyte stimulation and counts of rosetteforming cells". JNCI. 1974, 53, 641.
25. Nemoto T., Vana J., Bedwani R. N., Baker H. W., MsGregor E. H., Murphy G. P.: "Management and survival of female breast cancer: results of a national survey by the American College of Surgeons". Cancer, 1980, 45, 2917.
26. Yamamura J., Fudenberg A. H.: "Relationship between general immunological status and prognosis". In: Haskill S. (ed.): "Tumor immunity in prognosis. The role of mononuclear cell infiltration". New York, Basel., Delderi. 1982, 256.
27. Hasin N.: "Immune status in patients cured of breast and gynecologic cancer". Clin. Oncol., 1981, 7, 141.
28. Szigeti R.: "Application of migration inhibition techniques in tumor immunity". Adv. Cancer Res., 1985, 43, 241.
29. Abbate I., Correale M., Gargano G., Tedone T., Izzi E., Catino A. et al., "Tumor necrosis factor and soluble Interleukin-2 receptor: two immunological biomarkers in female neoplasms". Gynec. Oncol., 1992, 1, 92.
30. Rosenberg S. A., Mulé J. J.: "Immunotherapy of cancer with lymphokineactivated killer cells and recombinant interlukin-2". Surgery, 1985, 98, 437.
31. Lotze M. T., Chang A. E., Seipp C. A., Simpson C., Vetto J. T., Rosenberg S. A.: "High-dose recombinant interleukin-2 in the treatment of patients with disseminated cancer". J. Am. Med. Ass., 1986, 256, 3117.